Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update

Candel Therapeutics, Inc. (NASDAQ:CADL) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 1,590,000 shares, a drop of 5.9% from the September 15th total of 1,690,000 shares. Approximately 8.2% of the shares of the company are short sold. Based on an average trading volume of 285,900 shares, the short-interest ratio is presently 5.6 days.

Insider Activity at Candel Therapeutics

In related news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $6.02, for a total value of $90,300.00. Following the transaction, the insider now directly owns 929,873 shares in the company, valued at approximately $5,597,835.46. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last ninety days, insiders have sold 31,800 shares of company stock valued at $193,380. Corporate insiders own 41.60% of the company’s stock.

Institutional Trading of Candel Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CADL. Point72 DIFC Ltd bought a new position in shares of Candel Therapeutics in the second quarter worth $31,000. Cubist Systematic Strategies LLC bought a new stake in shares of Candel Therapeutics in the 2nd quarter valued at $162,000. Rhumbline Advisers bought a new stake in Candel Therapeutics in the second quarter valued at $143,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics in the 2nd quarter valued at about $338,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Candel Therapeutics Price Performance

Shares of NASDAQ:CADL traded down $0.20 during midday trading on Thursday, reaching $6.02. 72,255 shares of the company’s stock were exchanged, compared to its average volume of 1,973,376. Candel Therapeutics has a 12 month low of $0.66 and a 12 month high of $14.30. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.62 and a current ratio of 1.62. The company’s 50 day simple moving average is $6.33 and its two-hundred day simple moving average is $6.81. The firm has a market capitalization of $179.13 million, a PE ratio of -4.70 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.74) EPS for the quarter. Equities research analysts expect that Candel Therapeutics will post -0.91 earnings per share for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.